Parkinson’s disease (EP) is a devastating neurodegenerative disorder characterized by motorized impediments, tremors, stiffness and cognitive deterioration. While its exact cause is still difficult, new research suggests that cholesterol metabolism can play a fundamental role in its progression.
A recently published study in PLOS BIOLOGY By Professor Zhereo Zhang and his colleagues from the University of Wuhan they reveal that an oxidized cholesterol metabolite can contribute to two distinctive characteristics of the EP: the formation of Lewy bodies and the death of dopamine producing neurons (biology plo).
24-OHC role in Parkinson’s disease
In their study, the researchers observed that both Parkinson’s patients and disease mice models exhibited high levels of 24-OHC in the brain. To investigate their effects more thoroughly, modified and modified mice to eliminate CYP46A1, the enzyme responsible for converting cholesterol into 24-OHC. Notable, the absence of CYP46A1 reduced the propagation of Alfa-Sinuclein Fibrils harmful (α-SYN) that are added in toxic groups known as Lewy bodies, a key pathological characteristic of the EP. In addition, dopamine neuron loss was significantly mitigated in these modified mice.
In vitro experiments further confirmed the link between the 24-OHC and α-SYN pathology. When the researchers introduced 24-OHC in cultivated neurons, normal α-Syn fibrils became Harpulul, added forms. Moreover, the injection of toxic α-Syn fibrils in the brain of the mice led to a greater formation of Lewy’s body, degeneration of the dopamine neuron and a deteriorated motor function.
A new way for Parkinson’s treatment?
These findings highlight the potential to aim at cholesterol metabolism as a new therapeutic strategy for Parkinson’s disease. When inhibiting CYP46A1 or block the conversion of cholesterol into 24-OHC, researchers speculate that it may be possible to slow or even prevent the progression of the disease.
While more studies are needed to confirm the results of the thesis in humans, this research offers a new convincing director for the development of medicines. If cholesterol metabolism is in fact a driving factor in the pathology of EP, then existing cholesterol modifiers or new specific therapies could be promising to combat this weakening disorder.
Looking to the future
As the search for effective treatments of Parkinson continues, it is crucial to understand the intricate connections between metabolism and neurodegeneration. This study underlines the importance of metabolic processes in brain health and opens the new interventions that could alter the course of neurodegenerative diseases.
Could the handling of cholesterol metabolism the necessary advance for Parkinson’s treatment? Future clinical trials will determine whether this promising approach translates into real world benefits for patients.
